Jazz Pharmaceuticals PLC $JAZZ Shares Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp grew its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 44.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,679,371 shares of the specialty pharmaceutical company’s stock after purchasing an additional 517,514 shares during the period. Bank of New York Mellon Corp’s holdings in Jazz Pharmaceuticals were worth $317,485,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in JAZZ. Hilltop National Bank purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $36,000. LRI Investments LLC bought a new position in Jazz Pharmaceuticals in the fourth quarter worth about $38,000. Danske Bank A S acquired a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at approximately $40,000. Geneos Wealth Management Inc. increased its position in shares of Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in Jazz Pharmaceuticals by 1,383.3% during the third quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 332 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $247.53 on Friday. The stock has a market capitalization of $15.55 billion, a price-to-earnings ratio of -12,370.31, a PEG ratio of 0.21 and a beta of 0.32. Jazz Pharmaceuticals PLC has a 12 month low of $105.00 and a 12 month high of $250.49. The firm has a fifty day simple moving average of $235.11 and a 200 day simple moving average of $200.42. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The firm had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. Research analysts forecast that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Heather Ann Mcsharry sold 2,000 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $241.00, for a total value of $482,000.00. Following the completion of the sale, the director directly owned 18,449 shares of the company’s stock, valued at $4,446,209. The trade was a 9.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Neena M. Patil sold 1,200 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total transaction of $278,196.00. Following the transaction, the executive vice president owned 51,549 shares of the company’s stock, valued at $11,950,604.67. This represents a 2.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 13,098 shares of company stock valued at $3,131,906 in the last 90 days. Company insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on JAZZ shares. Weiss Ratings upgraded shares of Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, June 29th. Barclays increased their price objective on Jazz Pharmaceuticals from $253.00 to $260.00 and gave the company an “overweight” rating in a research report on Tuesday. Raymond James Financial restated an “outperform” rating and set a $239.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Sanford C. Bernstein restated a “market perform” rating on shares of Jazz Pharmaceuticals in a report on Tuesday, June 9th. Finally, Leerink Partners boosted their price target on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 22nd. Seventeen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $256.44.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.